Helix is a San Mateo-based population genomics company that helps health systems, life sciences companies, and public health organizations weave genomic data into everyday patient care. Built around its proprietary Exome+ assay and the first FDA-authorized whole exome sequencing platform, Helix powers large-scale precision health programs at partners like Mayo Clinic and Renown Health, with a research network spanning hundreds of thousands of sequenced participants.
Yongwei Zhang is the CEO of Complete Genomics and MGI Americas, leading one of the most ambitious efforts to make whole-genome sequencing fast, accurate, and affordable at scale. With a PhD in Mechanical Engineering from Johns Hopkins and dual bachelor's degrees from Tsinghua University, Zhang brings a rare blend of optics precision, software fluency, and entrepreneurial grit to the genomics frontier. He architected the DNBSEQ sequencing platform series now used by over 2,600 researchers in 100 countries, and has positioned Complete Genomics as a formidable challenger to Illumina's market dominance - at a fraction of the cost.